GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Median PS Value

ALZN (Alzamend Neuro) Median PS Value : $0.00 (As of Apr. 15, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Alzamend Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2025 was $0. Alzamend Neuro's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-15), Alzamend Neuro's share price is $0.76. Alzamend Neuro's Median PS Value is $0.00. Therefore, Alzamend Neuro's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Alzamend Neuro's Median PS Value or its related term are showing as below:

ALZN's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Alzamend Neuro Median PS Value Historical Data

The historical data trend for Alzamend Neuro's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Median PS Value Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Median PS Value
Get a 7-Day Free Trial - - - - -

Alzamend Neuro Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alzamend Neuro's Median PS Value

For the Biotechnology subindustry, Alzamend Neuro's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzamend Neuro's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Price-to-Median-PS-Value falls into.


;
;

Alzamend Neuro Median PS Value Calculation

Alzamend Neuro's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Alzamend Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro  (NAS:ALZN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Alzamend Neuro's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.76/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro Median PS Value Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro Business Description

Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
William B. Horne director C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Ault Milton C Iii 10 percent owner 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff officer: Chief Operating Officer 201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman director, officer: Chief Executive Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath director 28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson director 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
Henry Carl Nisser director, officer: Exec VP and General Counsel 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun officer: SVP of Finance 3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram director 15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien officer: Chief Financial Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo director 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404

Alzamend Neuro Headlines

From GuruFocus

Alzamend Neuro Announces Reverse Stock Split

By Business Wire 07-12-2024